Offering more than 150 oncology-specific tests in nine subspecialty areas, Mayo Clinic Laboratories’ cancer tests are developed by an experienced team of board-certified geneticists, genetic counselors, and physicians. Each assay is validated in collaboration with Mayo Clinic oncologists, pathologists, and laboratorians, whose clinical expertise enables test options that improve patient care and increase efficiency.
Mayo Clinic Laboratories innovates at the speed of medical advancement and offers full-spectrum testing across the oncological arena. From broad, next-generation sequencing (NGS) panels like MayoComplete, which examines more than 500 genes for variations associated with solid tumors; to advanced fluorescence in situ hybridization (FISH) testing for monitoring chronic lymphocytic leukemia; to polymerase chain reaction (PCR) for single genes evaluation; our molecular and cytogenetic assays span the oncological spectrum, providing insights on common and rare disease to advance clinical trials and therapeutic development.
In addition to accessing our clinically available tests, Mayo Clinic BioPharma Diagnostics partners can access oncological testing for clinical trials and be among the first to use up-and-coming tests currently in development.